• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by PureTech Health plc

    4/29/26 6:05:09 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTC alert in real time by email
    6-K 1 d37980d6k.htm 6-K 6-K
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

    For the month of April, 2026

    Commission File Number 001-39670

     

     

    PURETECH HEALTH PLC

    (Translation of registrant’s name into English)

     

     

    6 Tide Street, Suite 400

    Boston, Massachusetts 02210

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F  ☒    Form 40-F  ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

     

     
     


    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

    On April 29, 2026, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) issued a press release titled “PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange.”

    The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

    Exhibits

     

    99.1    Press Release of PureTech Health plc, dated April  29, 2026, titled “PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange.”


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      PURETECH HEALTH PLC
    Date: April 29, 2026   By:  

    /s/ Robert Lyne

        Name:   Robert Lyne
        Title:   Chief Executive Officer
    Get the next $PRTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRTC

    DatePrice TargetRatingAnalyst
    9/9/2024$58.00 → $45.00Outperform
    Leerink Partners
    1/7/2022$76.00 → $70.00Outperform
    SVB Leerink
    8/25/2021$74.00 → $76.00Outperform
    SVB Leerink
    More analyst ratings

    $PRTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

    Presentations to highlight differentiated approach to advancing deupirfenidone, reinforcing its potential to serve as a new standard of care within the evolving idiopathic pulmonary fibrosis treatment landscape PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced presentations showcasing its deupirfenidone (LYT-100) program at the upcoming American Thoracic Society (ATS) International Conference, taking place in Orlando, Florida, from May 15-20, 2026. Deupirfenidone is an investigational therapy being advanced by PureTech's Founded Ent

    5/13/26 7:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Announces Annual Results for Year Ended December 31, 2025

    Refined strategy and disciplined execution position Company to unlock value from its portfolio, which includes Celea Therapeutics' Phase 3-ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology's clinically-validated LYT-200 for myeloid malignancies, and Seaport Therapeutics' advancing clinical-stage pipeline for neuropsychiatric disorders PureTech level cash, cash equivalents and short-term investments of $277.1 million1 and Consolidated cash, cash equivalents and short-term investments of $277.3 million1 as of December 31, 2025; Operational runway at least through the end of 2028, inclusive of the Company's expected participation in Founded Entity fundraisings As of M

    4/29/26 2:01:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

    PureTech to maintain its primary listing on the London Stock Exchange Simplification of listing structure expected to enhance operational efficiency and focus resources on advancing the Company's portfolio PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that it has notified The Nasdaq Stock Market LLC ("Nasdaq") of its intention to voluntarily delist its American Depositary Shares ("ADSs"), each representing the right to receive ten (10) ordinary shares of the Company. Following the effectiveness of the delisting, PureTech's ord

    4/29/26 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners resumed coverage on PureTech Health plc with a new price target

    Leerink Partners resumed coverage of PureTech Health plc with a rating of Outperform and set a new price target of $45.00 from $58.00 previously

    9/9/24 7:42:36 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on PureTech Health with a new price target

    SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $70.00 from $76.00 previously

    1/7/22 4:34:06 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on PureTech Health with a new price target

    SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $76.00 from $74.00 previously

    8/25/21 4:40:14 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Puretech Health Plc converted options into 16,382,534 shares (SEC Form 4)

    4 - PureTech Health plc (0001782999) (Reporting)

    5/6/26 7:38:15 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Puretech Health Plc claimed ownership of 302,479 shares (SEC Form 3)

    3 - PureTech Health plc (0001782999) (Reporting)

    4/30/26 9:35:10 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the appointment of Dr. Sharon Mates to its Board of Directors. Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately $14.6 billion. She has decades of experience in neuropsychiatry, guiding a company she founded through successful commercialization and a major st

    4/27/26 7:05:00 AM ET
    $BNTC
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Appoints Robert Lyne as Chief Executive Officer

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217152848/en/Robert Lyne, Chief Executive Officer of PureTech Robert Lyne commented: "I'm honored to lead PureTech as CEO at such an important moment in its evolution. Over the past two years, I've seen first-hand the streng

    12/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Announces Leadership Transition

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces that Bharatt Chowrira, PhD, JD, has stepped down today from his role as Chief Executive Officer (CEO) and as a member of the Board of Directors. The Board of Directors has appointed Robert Lyne as Interim CEO with effect from today. Mr. Lyne joined PureTech as Chief Portfolio Officer in January 2024 and is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. He will continue to work closely with PureTe

    7/16/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Financials

    Live finance-specific insights

    View All

    PureTech Health: Notice of Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2025, on Wednesday, April 29, 2026. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D mo

    4/13/26 2:05:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Health: Notice of Half-Yearly Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep port

    8/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Health: Notice of Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a b

    4/23/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PureTech Health plc

    SC 13G - PureTech Health plc (0001782999) (Subject)

    11/12/24 1:29:13 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PureTech Health plc

    SC 13G/A - PureTech Health plc (0001782999) (Subject)

    11/7/24 9:47:57 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by PureTech Health plc (Amendment)

    SC 13G/A - PureTech Health plc (0001782999) (Subject)

    2/12/24 4:48:30 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    SEC Filings

    View All

    SEC Form F-6 POS filed by PureTech Health plc

    F-6 POS - PureTech Health plc (0001782999) (Subject)

    5/22/26 12:21:26 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by PureTech Health plc

    424B3 - PureTech Health plc (0001782999) (Filer)

    5/21/26 10:31:31 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15F-12B filed by PureTech Health plc

    15F-12B - PureTech Health plc (0001782999) (Filer)

    5/21/26 8:32:06 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care